Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of PRO-155 (Zebesten Ofteno®) on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.

NCT03521791 is registered in ClinicalTrials.gov with Laboratorios Sophia S.A de C.V. as lead sponsor.

NCT NCT03521791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03521791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of PRO-155 (Zebesten Ofteno®) on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.
Lead sponsor
Laboratorios Sophia S.A de C.V.
Phase
Phase 4
Overall status
Completed
Start date
December 13, 2017
Completion date
October 31, 2018
Enrollment
166 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

ocular inflammation, ocular pain, post-surgical inflammation, pterygium